Status:
COMPLETED
A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The goal of the study is to learn what happens to different forms of enlicitide medications in a healthy person's body over time. Researchers will compare the amount of enlicitide in the healthy perso...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior
- Has body mass index (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2
Exclusion
- The main exclusion criteria include but are not limited to the following:
- Has history of gastrointestinal disease which may affect food and drug absorption or has had a gastric bypass or similar surgery
- Has history of cancer (malignancy)
- Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
Key Trial Info
Start Date :
April 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06880874
Start Date
April 2 2025
End Date
May 31 2025
Last Update
June 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion ( Site 0001)
Tempe, Arizona, United States, 85283